We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Xeljanz Effective Against COVID-19 Pneumonia, Study Shows
Pfizer’s Xeljanz Effective Against COVID-19 Pneumonia, Study Shows
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz (tofacitinib) reduced the incidence of death or respiratory failure among hospitalized patients with COVID-19 pneumonia in a Brazilian study.